文献速递消化系统肿瘤

腹腔热灌注化疗对胃癌同步腹膜转移根治性手术的影响:III期GASTRIPEC-I试验

Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.
PubMed 文献 · J Clin Oncol · 2023-10-31

这项随机、对照、开放标签、多中心III期试验纳入105例胃癌伴组织学证实腹膜转移的成人患者,1:1随机分配至围手术期化疗联合单纯根治性手术(CRS-A)或根治性手术联合腹腔热灌注化疗(CRS+H)。结果显示两组中位总生存期相同(均为14.9个月),CRS+H组无进展生存期和远处转移无生存期显著更优,且未增加不良事件。

要点

  • 两组中位总生存期均为14.9个月,无统计学差异(P=.1647)。
  • CRS+H组中位无进展生存期7.1个月 vs CRS-A组3.5个月(P=.047)。
  • CRS+H组中位远处转移无生存期10.2个月 vs CRS-A组9.2个月(P=.0286)。

核心结论

  • 本研究显示根治性手术联合腹腔热灌注化疗与单纯根治性手术相比,总生存期无差异。
  • 根治性手术联合腹腔热灌注化疗组的无进展生存期和远处转移无生存期显著更优,需进一步探索。
  • 腹腔热灌注化疗未增加不良事件。

研究设计与样本

  • 随机、对照、开放标签、多中心III期试验(EudraCT 2006-006088-22;ClinicalTrials.gov NCT02158988)。
  • 纳入胃癌伴组织学证实腹膜转移的成人患者,1:1随机分配至围手术期化疗联合单纯根治性手术(CRS-A)或根治性手术联合腹腔热灌注化疗(CRS+H)。
  • 腹腔热灌注化疗方案为丝裂霉素C 15 mg/m²和顺铂75 mg/m²溶于5 L生理盐水,42°C灌注60分钟。
  • 主要终点为总生存期,次要终点包括无进展生存期、其他远处转移无生存期和安全性,采用意向性治疗分析。
  • 2014年3月至2018年6月共随机分配105例患者(CRS-A组53例,CRS+H组52例),因招募缓慢提前终止;55例患者在根治性手术前停止治疗,主要因疾病进展/死亡。

主要发现

  • 中位总生存期两组相同:CRS+H组14.9个月(97.2% CI, 8.7至17.7)vs CRS-A组14.9个月(97.2% CI, 7.0至19.4),P=.1647。
  • 中位无进展生存期:CRS-A组3.5个月(95% CI, 3.0至7.0)vs CRS+H组7.1个月(95% CI, 3.7至10.5),P=.047。
  • 中位远处转移无生存期:CRS+H组10.2个月(95% CI, 7.7至14.7)vs CRS-A组9.2个月(95% CI, 6.8至11.5),P=.0286。
  • ≥3级不良事件发生率两组相似:CRS-A组38.1% vs CRS+H组43.6%,P=.79。

关键数值与推荐

  • 腹腔热灌注化疗方案:丝裂霉素C 15 mg/m²和顺铂75 mg/m²溶于5 L生理盐水,42°C灌注60分钟。

临床怎么用

  • 原文未据此给出推荐。
  • 作者指出无进展生存期和远处转移无生存期的优势需进一步探索。

局限性

  • 试验因招募缓慢提前终止。
  • 55例患者在根治性手术前停止治疗,主要因疾病进展/死亡。
  • 无进展生存期和远处转移无生存期的优势需进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with peritoneal metastasis (PM) from gastric cancer (GC), chemotherapy is the treatment of choice. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are still being debated. This randomized, controlled, open-label, multicenter phase III trial (EudraCT 2006-006088-22; ClinicalTrials.gov identifier: NCT02158988) explored the impact on overall survival (OS) of HIPEC after CRS. PATIENTS AND METHODS: Adult patients with GC and histologically proven PM were randomly assigned (1:1) to perioperative chemotherapy and CRS alone (CRS-A) or CRS plus HIPEC (CRS + H). HIPEC comprised mitomycin C 15 mg/m2 and cisplatin 75 mg/m2 in 5 L of saline perfused for 60 minutes at 42°C. The primary end point was OS; secondary endpoints included progression-free survival (PFS), other distant metastasis-free survival (MFS), and safety. Analyses followed the intention-to-treat principle. RESULTS: Between March 2014 and June 2018, 105 patients were randomly assigned (53 patients to CRS-A and 52 patients to CRS + H). The trial stopped prematurely because of slow recruitment. In 55 patients, treatment stopped before CRS mainly due to disease progression/death. Median OS was the same for both groups (CRS + H, 14.9 [97.2% CI, 8.7 to 17.7] months v CRS-A, 14.9 [97.2% CI, 7.0 to 19.4] months; P = .1647). The PFS was 3.5 months (95% CI, 3.0 to 7.0) in the CRS-A group and 7.1 months (95% CI, 3.7 to 10.5; P = .047) in the CRS + H group. The CRS + H group showed better MFS (10.2 months [95% CI, 7.7 to 14.7] v CRS-A, 9.2 months [95% CI, 6.8 to 11.5]; P = .0286). The incidence of grade ≥3 adverse events (AEs) was similar between groups (CRS-A, 38.1% v CRS + H, 43.6%; P = .79). CONCLUSION: This study showed no OS difference between CRS + H and CRS-A. PFS and MFS were significantly better in the CRS + H group, which needs further exploration. HIPEC did not increase AEs.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rau B, Lang H, Koenigsrainer A, et al. Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial. J Clin Oncol. 2023. PMID: 37906724. doi:10.1200/JCO.22.02867

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。